Quick Answer
Lyra Therapeutics, Inc. reported Operating Income of -$31.02 million for fiscal year 2025.
Lyra Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$31.02M | +67.8% |
| 2024 | -$96.35M | -43.5% |
| 2023 | -$67.12M | -19.2% |
| 2022 | -$56.31M | -29.1% |
| 2021 | -$43.62M | -96.4% |
| 2020 | -$22.21M | -34.4% |
| 2019 | -$16.52M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.24M | +49.9% | +29.3% |
| June 30, 2025 | -$8.83M | +82.0% | +0.2% |
| March 31, 2025 | -$8.84M | +62.4% | +28.9% |
| September 30, 2024 | -$12.44M | +26.1% | +74.6% |
| June 30, 2024 | -$48.97M | -196.8% | -108.2% |
| March 31, 2024 | -$23.52M | -35.9% | -39.8% |
| September 30, 2023 | -$16.83M | -13.5% | -2.0% |
| June 30, 2023 | -$16.50M | -14.6% | +4.7% |
- Lyra Therapeutics, Inc. showed an increase of +67.8% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s operating income has declined by 87.8% (from -$16.52 million to -$31.02 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: